X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs TORRENT PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA TORRENT PHARMA SANOFI INDIA/
TORRENT PHARMA
 
P/E (TTM) x 38.4 48.1 79.9% View Chart
P/BV x 7.2 6.5 110.9% View Chart
Dividend Yield % 0.5 0.8 66.8%  

Financials

 SANOFI INDIA   TORRENT PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-17
TORRENT PHARMA
Mar-18
SANOFI INDIA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs4,9451,550 319.0%   
Low Rs3,9011,144 341.1%   
Sales per share (Unadj.) Rs1,081.8354.7 305.0%  
Earnings per share (Unadj.) Rs141.640.1 353.2%  
Cash flow per share (Unadj.) Rs185.964.2 289.5%  
Dividends per share (Unadj.) Rs33.0014.00 235.7%  
Dividend yield (eoy) %0.71.0 71.8%  
Book value per share (Unadj.) Rs868.8273.1 318.1%  
Shares outstanding (eoy) m23.03169.22 13.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.13.8 107.7%   
Avg P/E ratio x31.233.6 93.0%  
P/CF ratio (eoy) x23.821.0 113.4%  
Price / Book Value ratio x5.14.9 103.3%  
Dividend payout %23.334.9 66.7%   
Avg Mkt Cap Rs m101,862227,897 44.7%   
No. of employees `0003.214.7 22.0%   
Total wages/salary Rs m3,68511,353 32.5%   
Avg. sales/employee Rs Th7,691.94,083.0 188.4%   
Avg. wages/employee Rs Th1,137.7772.3 147.3%   
Avg. net profit/employee Rs Th1,006.5461.3 218.2%   
INCOME DATA
Net Sales Rs m24,91460,021 41.5%  
Other income Rs m8072,988 27.0%   
Total revenues Rs m25,72163,009 40.8%   
Gross profit Rs m5,37213,493 39.8%  
Depreciation Rs m1,0224,086 25.0%   
Interest Rs m113,085 0.4%   
Profit before tax Rs m5,1469,310 55.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8862,529 74.6%   
Profit after tax Rs m3,2606,781 48.1%  
Gross profit margin %21.622.5 95.9%  
Effective tax rate %36.627.2 134.9%   
Net profit margin %13.111.3 115.8%  
BALANCE SHEET DATA
Current assets Rs m14,43252,623 27.4%   
Current liabilities Rs m6,01052,022 11.6%   
Net working cap to sales %33.81.0 3,373.2%  
Current ratio x2.41.0 237.4%  
Inventory Days Days61120 50.9%  
Debtors Days Days2876 37.4%  
Net fixed assets Rs m7,99185,016 9.4%   
Share capital Rs m230846 27.2%   
"Free" reserves Rs m19,77845,376 43.6%   
Net worth Rs m20,00846,222 43.3%   
Long term debt Rs m041,115 0.0%   
Total assets Rs m27,770142,432 19.5%  
Interest coverage x468.84.0 11,667.8%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.90.4 212.9%   
Return on assets %11.86.9 170.0%  
Return on equity %16.314.7 111.1%  
Return on capital %25.814.2 181.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6,30614,580 43.3%   
Fx outflow Rs m5,2573,600 146.0%   
Net fx Rs m1,04910,980 9.6%   
CASH FLOW
From Operations Rs m4,3518,942 48.7%  
From Investments Rs m-787-47,070 1.7%  
From Financial Activity Rs m-1,88434,174 -5.5%  
Net Cashflow Rs m1,680-3,655 -46.0%  

Share Holding

Indian Promoters % 0.0 71.5 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 7.0 205.1%  
FIIs % 14.6 12.6 115.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 8.8 119.3%  
Shareholders   15,184 26,511 57.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON LTD  FULFORD INDIA  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Telecom and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets continued to trade near the dotted line during closing hours and ended the day marginally higher. Gains were largely seen in the telecom sector.

Related Views on News

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Dec 14, 2018 03:35 PM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - PIRAMAL ENTERPRISES COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS